JP2021516989A5 - - Google Patents

Download PDF

Info

Publication number
JP2021516989A5
JP2021516989A5 JP2020554837A JP2020554837A JP2021516989A5 JP 2021516989 A5 JP2021516989 A5 JP 2021516989A5 JP 2020554837 A JP2020554837 A JP 2020554837A JP 2020554837 A JP2020554837 A JP 2020554837A JP 2021516989 A5 JP2021516989 A5 JP 2021516989A5
Authority
JP
Japan
Prior art keywords
antibody
chain variable
variable region
sequence
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516989A (ja
JP7104458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/080847 external-priority patent/WO2019192432A1/zh
Publication of JP2021516989A publication Critical patent/JP2021516989A/ja
Publication of JP2021516989A5 publication Critical patent/JP2021516989A5/ja
Application granted granted Critical
Publication of JP7104458B2 publication Critical patent/JP7104458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554837A 2018-04-02 2019-04-01 リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用 Active JP7104458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018081636 2018-04-02
CNPCT/CN2018/081636 2018-04-02
PCT/CN2019/080847 WO2019192432A1 (zh) 2018-04-02 2019-04-01 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途

Publications (3)

Publication Number Publication Date
JP2021516989A JP2021516989A (ja) 2021-07-15
JP2021516989A5 true JP2021516989A5 (cg-RX-API-DMAC7.html) 2021-09-02
JP7104458B2 JP7104458B2 (ja) 2022-07-21

Family

ID=68099943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554837A Active JP7104458B2 (ja) 2018-04-02 2019-04-01 リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用

Country Status (4)

Country Link
US (1) US11840568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3778639A4 (cg-RX-API-DMAC7.html)
JP (1) JP7104458B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019192432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202904A1 (en) 2020-04-03 2021-10-07 Sorrento Therapeutics, Inc. Engineered antibodies that bind lags

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
WO2015116539A1 (en) 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
EA201691765A1 (ru) * 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016033547A1 (en) * 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and oprl
CN114456272A (zh) * 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
JP6468962B2 (ja) 2015-07-03 2019-02-13 日立造船株式会社 クレーン干渉チェックシステム、橋梁架設シミュレーションシステム、及び、それらを備えた3d施工計画システム

Similar Documents

Publication Publication Date Title
JP2021530251A5 (cg-RX-API-DMAC7.html)
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2019201643A5 (cg-RX-API-DMAC7.html)
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2017048240A5 (cg-RX-API-DMAC7.html)
JP2020536504A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2013198490A5 (cg-RX-API-DMAC7.html)
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2021514973A5 (cg-RX-API-DMAC7.html)
JP2018522888A5 (cg-RX-API-DMAC7.html)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2018510636A5 (cg-RX-API-DMAC7.html)
JP2020514277A5 (cg-RX-API-DMAC7.html)
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2013519364A5 (cg-RX-API-DMAC7.html)
JP2021502984A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2019505477A5 (cg-RX-API-DMAC7.html)